Abstract: Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.
Type:
Grant
Filed:
April 8, 2016
Date of Patent:
June 27, 2017
Assignee:
APPLIED PROTEOMICS, INC.
Inventors:
John Blume, Jeffrey Jones, Ryan Benz, Athit Kao, Lisa Croner, Roslyn Dillon, Jia You, Bruce Wilcox
Abstract: The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, and binding agents for the markers. Methods of identifying a subject having oral dysplasia that is at high risk of malignant transformation are provided.
Abstract: Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for measuring the degree of the test compound's anti-neoplastic activity upon a cancer tissue by providing a test compound to a cancer tissue sample and measuring the degree of methylation of nucleotides within the 5? region in the cancer tissue sample.
Type:
Grant
Filed:
October 10, 2008
Date of Patent:
June 13, 2017
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
Type:
Grant
Filed:
July 18, 2011
Date of Patent:
May 30, 2017
Assignee:
INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH
Inventors:
Claudine Vermot-Desroches, Boris Sebastien Vuillermoz
Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.
Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
Type:
Grant
Filed:
June 29, 2016
Date of Patent:
April 25, 2017
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors:
William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold S. Bergen, III, David I. Smith, David A. Ahlquist
Abstract: Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer.
Type:
Grant
Filed:
October 1, 2009
Date of Patent:
April 18, 2017
Assignee:
Myriad Genetics, Inc.
Inventors:
Julian R. Sampson, Jeremy Peter Cheadle
Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.
Type:
Grant
Filed:
January 26, 2015
Date of Patent:
April 11, 2017
Assignee:
The Regents of the University of Michigan
Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.
Type:
Grant
Filed:
April 16, 2014
Date of Patent:
April 4, 2017
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison
Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc?R receptors except with Fc?RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.
Type:
Grant
Filed:
September 22, 2014
Date of Patent:
April 4, 2017
Assignee:
Janssen Biotech, Inc.
Inventors:
Randall Brezski, Robert Jordan, William Strohl
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Abstract: The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
March 14, 2017
Assignee:
The Johns Hopkins University
Inventors:
Hui Zhang, Yuan Tian, Daniel W. Chan, Jing Chen
Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr 51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
March 14, 2017
Assignee:
H. Lee Moffitt Cancer Center and Research Institute
Abstract: A novel method that enables prostate cancer testing that is noninvasive and more accurate than conventional methods is disclosed. The present inventors intensively analyzed urine samples from prostate cancer patients, and non-cancer subjects, who are free of prostate cancer, and, as a result, newly discovered urinary peptides that can be used as indicators in prostate cancer testing. Use of these urinary peptides as indicators enables various prostate cancer-related tests including detection of prostate cancer, discrimination between prostate cancer and benign prostatic hyperplasia, monitoring of a therapeutic effect of prostate cancer therapy and monitoring of postoperative recurrence.
Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.
Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
January 3, 2017
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
George Vasmatzis, John C. Cheville, Farhad Kosari, Cemile D. Savci-Heijink, Eric W. Klee, Jan Marie A. Willard, Lori S. Tillmans